Cargando…

Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study

BACKGROUND: Cases of impaired renal function have been reported in patients who had been treated with both zoledronic acid and thalidomide for myeloma. Hence, we conducted a safety study of zoledronic acid and thalidomide in myeloma patients participating in a trial of maintenance therapy. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spencer, Andrew, Roberts, Andrew, Kennedy, Nola, Ravera, Christina, Cremers, Serge, Bilic, Sanela, Neeman, Terry, Copeman, Michael, Schran, Horst, Lynch, Kevin
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2330021/ https://www.ncbi.nlm.nih.gov/pubmed/18377658 http://dx.doi.org/10.1186/1472-6904-8-2

Ejemplares similares

Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
por: Buscarini, Elisabetta, et al.
Publicado: (2019)

Efficacy and Safety of Thalidomide for Chemotherapy-induced Nausea and Vomiting
por: Wang, Nan, et al.
Publicado: (2020)

Thalidomide and its analogues in the treatment of Multiple Myeloma
por: Latif, Tahir, et al.
Publicado: (2012)

Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study
por: Yin, Qing-song, et al.
Publicado: (2016)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Adverse Effects of Thalidomide Administration, in Patients with Myeloma Multiplex?
por: Svetlana Balkanov, Krstevska, et al.
Publicado: (2014)

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
por: Badros, A Z, et al.
Publicado: (2013)

Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome
por: Kakimoto, Tsunayuki, et al.
Publicado: (2002)

Reversible Pulmonary Hypertension Related to Thalidomide Treatment for Multiple Myeloma
por: Villa, Antonio, et al.
Publicado: (2011)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
por: Castro, T.B.M., et al.
Publicado: (2016)

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
por: Cury, Priscilla Cury de Camargo, et al.
Publicado: (2020)

Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors
por: Savelieva, Marina, et al.
Publicado: (2015)

Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
por: Dalle Carbonare, Luca, et al.
Publicado: (2010)

Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis
por: Serefoglu, Ege Can, et al.
Publicado: (2010)

Efficacy and safety of thalidomide in two sisters with severe refractory polyarteritis nodosa (PAN)
por: Vitale, A, et al.
Publicado: (2008)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
por: Del Fabro, V., et al.
Publicado: (2023)

A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
por: Barrett, Doreen, et al.
Publicado: (2021)

Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma
por: Kang, Myung-Hee, et al.
Publicado: (2010)

Acute Pulmonary Toxicity from Thalidomide in a Patient with Multiple Myeloma
por: Khalsa, Satkirin K., et al.
Publicado: (2015)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma
por: Wang, Yu, et al.
Publicado: (2023)

Safety & Efficacy of Cyclic Zoledronic Acid Therapy on Pediatric Secondary Osteoporosis
por: Al-Agha, Abdulmoein E., et al.
Publicado: (2016)

Safety and Efficacy of Zoledronic Acid Treatment with and without Acetaminophen and Eldecalcitol for Osteoporosis
por: Mochizuki, Takeshi, et al.
Publicado: (2021)

Investigating the Efficacy and Safety of Thalidomide for Treating Patients With ß-Thalassemia: A Meta-Analysis
por: Lu, Yanfei, et al.
Publicado: (2022)

Pharmacokinetics of thalidomide in dogs: can feeding affect it? A preliminary study
por: Pierini, Alessio, et al.
Publicado: (2020)

Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
por: Quach, Hang, et al.
Publicado: (2017)

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
por: Kim, Cheolsu, et al.
Publicado: (2015)

Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model
por: Nourinia, Ramin, et al.
Publicado: (2014)

Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid
por: Kmetec, Andrej, et al.
Publicado: (2013)

Thalidomide—Then and Now: Case Report of a Woman With Thalidomide Embryopathy and Review of Current Thalidomide Uses
por: Malik, Sara, et al.
Publicado: (2021)

Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial
por: Chen, Jiang-Ming, et al.
Publicado: (2021)

Efficacy and safety of low-dose thalidomide combined with mesalazine in the treatment of refractory ulcerative colitis in adults
por: Chen, Jun-Rong, et al.
Publicado: (2022)

A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma
por: Spencer, Andrew, et al.
Publicado: (2019)

Cardiovascular Safety in Postmenopausal Women and Men With Osteoporosis Treated With Denosumab and Zoledronic Acid: A Post‐Authorization Safety Study
por: Spangler, Leslie, et al.
Publicado: (2023)

Therapeutic effects of thalidomide in myeloma are associated with the expression of fibroblast growth factor receptor 3
por: Qian, Shenxian, et al.
Publicado: (2005)

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
por: Kang, Wonseok, et al.
Publicado: (2010)

Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma
por: Robak, Marta, et al.
Publicado: (2012)

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
por: Garcia, M Kay, et al.
Publicado: (2014)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f9s31urp259qa43q1tpdorctp4